[HTML][HTML] NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …
Targeting TRK family proteins in cancer
YB Khotskaya, VR Holla, AF Farago, KRM Shaw… - Pharmacology & …, 2017 - Elsevier
The tropomyosin receptor kinase (TRK) family includes TRKA, TRKB, and TRKC proteins,
which are encoded by NTRK1, NTRK2 and NTRK3 genes, respectively. Binding of …
which are encoded by NTRK1, NTRK2 and NTRK3 genes, respectively. Binding of …
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
[HTML][HTML] Molecular characterization of cancers with NTRK gene fusions
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients
with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently …
with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently …
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
Background Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of
various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with …
various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with …
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
R Okamura, A Boichard, S Kato, JK Sicklick… - JCO precision …, 2018 - ascopubs.org
Purpose Fusions that involve neurotrophic-tropomyosin receptor kinase (NTRK) genes are
known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active …
known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active …
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1
rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung …
rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung …
[HTML][HTML] JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with …
T Yoshino, G Pentheroudakis, S Mishima… - Annals of …, 2020 - Elsevier
Highlights•The PD-1 antibody pembrolizumab and the TRK inhibitors larotrectinib and
entrectinib recently received regulatory approval.•Such tumour-agnostic regulatory …
entrectinib recently received regulatory approval.•Such tumour-agnostic regulatory …
Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins
ES Kheder, DS Hong - Clinical Cancer Research, 2018 - AACR
The oncogenesis-promoting role of chromosomal rearrangements for several hematologic
and solid malignancies is well recognized. However, identifying targetable, actionable, and …
and solid malignancies is well recognized. However, identifying targetable, actionable, and …
[HTML][HTML] Entrectinib, a new multi-target inhibitor for cancer therapy
Q Jiang, M Li, H Li, L Chen - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Clinical practice shows that when single-target drugs treat multi-factor diseases such as
tumors, cardiovascular system and endocrine system diseases, it is often difficult to achieve …
tumors, cardiovascular system and endocrine system diseases, it is often difficult to achieve …